Medtronic plc (NYSE:MDT) SVP Carol A. Surface Sells 15,000 Shares

Medtronic plc (NYSE:MDT) SVP Carol A. Surface sold 15,000 shares of the business’s stock in a transaction on Monday, December 28th. The stock was sold at an average price of $114.90, for a total transaction of $1,723,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

MDT stock opened at $117.14 on Friday. The company has a quick ratio of 1.79, a current ratio of 2.16 and a debt-to-equity ratio of 0.52. Medtronic plc has a twelve month low of $72.13 and a twelve month high of $122.15. The stock has a market capitalization of $157.67 billion, a price-to-earnings ratio of 44.71, a price-to-earnings-growth ratio of 3.58 and a beta of 0.69. The firm’s fifty day simple moving average is $113.17 and its two-hundred day simple moving average is $104.05.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Monday, November 23rd. The medical technology company reported $1.02 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.80 by $0.22. Medtronic had a net margin of 12.69% and a return on equity of 9.71%. The business had revenue of $7.65 billion for the quarter, compared to analysts’ expectations of $7.05 billion. During the same quarter in the previous year, the business posted $0.45 earnings per share. As a group, equities research analysts expect that Medtronic plc will post 4.2 EPS for the current year.

Several equities analysts have recently commented on the stock. Wolfe Research assumed coverage on shares of Medtronic in a report on Friday, September 11th. They issued a “peer perform” rating and a $115.00 target price on the stock. Morgan Stanley raised shares of Medtronic from an “equal weight” rating to an “overweight” rating and set a $140.00 target price on the stock in a report on Tuesday, December 15th. Credit Suisse Group boosted their target price on shares of Medtronic from $118.00 to $126.00 and gave the stock an “outperform” rating in a report on Wednesday, November 25th. Smith Barney Citigroup boosted their target price on shares of Medtronic from $120.00 to $128.00 in a report on Wednesday, November 25th. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell boosted their target price on shares of Medtronic from $120.00 to $128.00 in a report on Wednesday, November 25th. Two analysts have rated the stock with a sell rating, three have issued a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $121.41.

A number of hedge funds have recently bought and sold shares of MDT. BlackRock Inc. increased its position in Medtronic by 4.1% during the second quarter. BlackRock Inc. now owns 111,209,886 shares of the medical technology company’s stock valued at $10,197,948,000 after acquiring an additional 4,352,426 shares during the last quarter. Two Sigma Advisers LP grew its holdings in shares of Medtronic by 393.8% in the second quarter. Two Sigma Advisers LP now owns 1,574,920 shares of the medical technology company’s stock worth $144,420,000 after purchasing an additional 1,255,988 shares during the last quarter. Coho Partners Ltd. bought a new position in shares of Medtronic in the third quarter worth about $124,511,000. Nuveen Asset Management LLC grew its holdings in shares of Medtronic by 14.3% in the third quarter. Nuveen Asset Management LLC now owns 7,627,002 shares of the medical technology company’s stock worth $792,599,000 after purchasing an additional 955,250 shares during the last quarter. Finally, Polar Capital LLP grew its holdings in shares of Medtronic by 159.2% in the third quarter. Polar Capital LLP now owns 1,169,376 shares of the medical technology company’s stock worth $121,522,000 after purchasing an additional 718,244 shares during the last quarter. Institutional investors and hedge funds own 68.87% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group, and Diabetes Group.

Featured Article: Price to Earnings Ratio (PE)

Insider Buying and Selling by Quarter for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.